Dysregulation of mTORC1 signaling plays a key role in the oncogenesis and progression of ccRCC, and hyperactivation of mTOR correlates with poor outcome in ccRCC patients. This evidence concerns the gene MTOR and nonpapillary renal cell carcinoma.